Feed aggregator

Nanotechnology-based CRISPR/Cas9 delivery system for genome editing in cancer treatment

World Pharma News - Wed, 01/31/2024 - 11:00
This review is designed by Professor Changyang Gong and written by his PhD student Shiyao Zhou. At the beginning, they elaborated the mechanism of CRISPR/Cas9 system. CRISPR/Cas9 system consists of Cas9 protein and single stranded directing RNA (sgRNA). In the presence of protospacer adjacent motif (PAM), sgRNA accurately leads the Cas9 endonuclease to the target regions, where it causes DNA double strand breaks (DSBs), resulting in site‐specific genomic change.

Up to three daily servings of kimchi may lower men's obesity risk

World Pharma News - Tue, 01/30/2024 - 11:00
Eating up to three daily servings of the Korean classic, kimchi, may lower men's overall risk of obesity, while radish kimchi is linked to a lower prevalence of midriff bulge in both sexes, finds research published in the open access journal BMJ Open.

Kimchi is made by salting and fermenting vegetables with various flavourings and seasonings, such as onion, garlic, and fish sauce.

New technology makes cancer easier for immune system to find and destroy

World Pharma News - Mon, 01/29/2024 - 11:00
A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer.

Major histocompatibility complex (MHC) class I molecules are an immune complex present on the surface of all cells in humans. MHC class I molecules are a prerequisite for the immune system to recognize and eliminate cancer.

'Cancer-cooling' protein puts bowel cancer on ice

World Pharma News - Fri, 01/26/2024 - 11:00
A protein in the immune system can be manipulated to help overcome bowel cancer, according to new research from The Australian National University (ANU).

Bowel cancer claims more than 100 lives in Australia each week, yet around 90 per cent of cases can be successfully treated if detected early.

Autonomous synthesis robot uses AI to speed up chemical discovery

World Pharma News - Thu, 01/25/2024 - 11:00
Chemists of the University of Amsterdam (UvA) have developed an autonomous chemical synthesis robot with an integrated AI-driven machine learning unit. Dubbed 'RoboChem', the benchtop device can outperform a human chemist in terms of speed and accuracy while also displaying a high level of ingenuity. As the first of its kind, it could significantly accelerate chemical discovery of molecules for pharmaceutical and many other applications.

Could two drugs be better than one for treating prostate cancer?

World Pharma News - Wed, 01/24/2024 - 11:00
Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found.

The approach can extend the time between debilitating drug treatments without prolonging the time it takes to recover from each treatment.

Bayer aims to sustainably improve performance with new organization

World Pharma News - Tue, 01/23/2024 - 11:00
The Bayer Group is introducing a new operating model called "Dynamic Shared Ownership" (DSO) worldwide, which will reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes. The aim of the new operating model is to make the company much more agile and significantly improve its operational performance.

New medicine can create a new life for diabetes patients - without needles

World Pharma News - Mon, 01/22/2024 - 11:00
There are approximately 425 million people worldwide with diabetes. Approximately 75 million of these inject themselves with insulin daily. Now they may soon have a new alternative to syringes or insulin pumps. Scientists have found a new way to supply the body with smart insulin.

The new insulin can be eaten by taking a capsule or even better, within a piece chocolate.

Complement system causes cell damage in Long COVID

World Pharma News - Fri, 01/19/2024 - 11:00
Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of manifestations. The causes and disease mechanisms of Long COVID are still unknown, and there are no diagnostic tests or targeted treatments.

Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation

World Pharma News - Thu, 01/18/2024 - 11:00
Pfizer Inc. (NYSE: PFE) announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 4 million shares of Pfizer common stock at a price of $27.35 per share in cash. TRC Capital Investment's offer price of $27.35 per share is approximately 4.4 percent lower than the $28.61 closing share price of Pfizer's common stock on December 27, 2023 - the business day prior to the date of the offer.

European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

World Pharma News - Wed, 01/17/2024 - 11:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)'s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians

Molecular 'super-glue' shows promise of cancer drug discovery platform

World Pharma News - Tue, 01/16/2024 - 11:00
Today, St. Jude Children's Research Hospital scientists published their work on SJ3149, a compound with broad activity against many cancer types, particularly acute myeloid leukemia (AML). SJ3149 sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to its destruction. The findings were reported in Nature Communications.

Accelerating how new drugs are made with machine learning

World Pharma News - Mon, 01/15/2024 - 11:00
Researchers have developed a platform that combines automated experiments with AI to predict how chemicals will react with one another, which could accelerate the design process for new drugs.

Predicting how molecules will react is vital for the discovery and manufacture of new pharmaceuticals, but historically this has been a trial-and-error process, and the reactions often fail.

Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)

World Pharma News - Fri, 01/12/2024 - 11:00
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced the initiation of GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).

mRNA technology could be possible treatment for rare diseases

World Pharma News - Thu, 01/11/2024 - 11:00
By exploiting the technology used in COVID-19 vaccines, a team led by UCL, King's College London and Moderna scientists has created an effective therapy for a rare disease, in a study in mice, demonstrating the technology’s potential therapeutic use in people.

The research, published in Science Translational Medicine, found that messenger RNA (mRNA) could be used to correct a rare liver genetic disease known as argininosuccinic aciduria in a mouse model of the disease.

TIVDAK® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer

World Pharma News - Wed, 01/10/2024 - 11:00
Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Smart skin bacteria are able to secrete and produce molecules to treat acne

World Pharma News - Tue, 01/09/2024 - 11:00
International research led by the Translational Synthetic Biology Laboratory of the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University has succeeded in efficiently engineering Cutibacterium acnes -a type of skin bacterium- to produce and secrete a therapeutic molecule suitable for treating acne symptoms. The engineered bacterium has been validated in skin cell lines and its delivery has been validated in mice.

Creating novel amino acid nanoparticles with enhanced anticancer activity

World Pharma News - Mon, 01/08/2024 - 11:00
Amino acids, such as tyrosine and tryptophan, are the fundamental building blocks that make up proteins. These biomolecules have different chemical groups on each end and side chain, and so, have the natural ability to form a chain through the formation of an amide (peptide) bond. However, such linkages are weak and easily degraded under physiological conditions.

Major breakthrough unveils immune system's guardian: IKAROS

World Pharma News - Fri, 01/05/2024 - 11:00
In a scientific breakthrough that aids our understanding of the internal wiring of immune cells, researchers at Monash University in Australia have cracked the code behind IKAROS, an essential protein for immune cell development and protection against pathogens and cancer.

This disruptive research, led by the eminent Professor Nicholas Huntington of Monash University's Biomedicine Discovery Institute, is poised to reshape our comprehension of gene control networks and its impact on everything from eye colour to cancer susceptibility and design of novel therapies.

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson's disease meets primary endpoint

World Pharma News - Thu, 01/04/2024 - 11:00
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today the completion of the 18-month data collection in the Phase Ib clinical trial for AB-1005 (AAV2-GDNF), an investigational gene therapy for treating patients with Parkinson's disease (PD).